Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors: Kaniwa, N  Saito, Y  Aihara, M  Matsunaga, K  Tohkin, M  Kurose, K  Sawada, J  Furuya, H  Takahashi, Y  Muramatsu, M  Kinoshita, S  Abe, M  Ikeda, H  Kashiwagi, M  Song, Y  Ueta, M  Sotozono, C  Ikezawa, Z  Hasegawa, R   
Citation: Kaniwa N, etal., Pharmacogenomics. 2008 Nov;9(11):1617-22. doi: 10.2217/14622416.9.11.1617.
Pubmed: (View Article at PubMed) PMID:19018717
DOI: Full-text: DOI:10.2217/14622416.9.11.1617

INTRODUCTION: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening severe cutaneous adverse reactions. Recently, strong associations of HLA-B*1502 and HLA-B*5801 with carbamazepine- and allopurinol-induced severe cutaneous adverse reactions were found in Han Chinese patients, respectively, but ethnic differences in the associations have been reported. The objective of this study is to clarify the involvement of HLA-B*1502 and HLA-B*5801 in Japanese SJS/TEN patients. METHODS: HLA-B genotyping was performed on 58 Japanese SJS/TEN patients between July 2006 and April 2008 from multicenters in Japan. RESULTS: There were no HLA-B*1502 carriers among 58 SJS/TEN patients. This patient group included seven carbamazepine-related and 11 aromatic anti-epileptic agent-related SJS/TEN patients. In addition, there were five HLA-B*5801 carriers, which included four allopurinol-related SJS/TEN patients. CONCLUSION: While HLA-B*1502 is unlikely to be associated with carbamazepine-related or aromatic anti-epileptic agent-related SJS/TEN, HLA-B*5801 was significantly associated with allopurinol-related SJS/TEN in Japanese.


Disease Annotations
Phenotype Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 7364874
Created: 2013-10-04
Species: All species
Last Modified: 2013-10-04
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.